Multiple Myeloma: Discussions
ENG
BMT CTN 0702 (STaMINA) / AQUILA / AURIGA / CAR-PRISM
ASH 2024
High-risk smoldering myeloma: should we treat it and…
ENG
CC-92480-MM-002 / Dreamm-7 / Majestec-2 and Trimm-2 / IMMagine-1 / Cartitude-4
ASH 2024
RRMM - a lot of options to choose from
ENG
GMMG-HD10/DSMM-XX (MajesTEC-5) / Majestec-4/EMN30 Trial / GMMG-HD7
ASH 2024
NDMM - upfront bispecifics and CAR-T cells!?
Newly Diagnosed Multiple Myeloma
ENG
BMT CTN 0702
ASH 2024
Reducing waste in Myeloma
ENG
DREAMM-9
ASH 2024
Belantamab mafodotin in 1st line of…
ENG
AQUILA, CAR-PRISM
ASH 2024
Treatment of smoldering myeloma
ENG
BMT CTN 0702 (STaMINA)
ASH 2024
24hrs urine collection no longer necessary for…
ENG
Majestec-4/EMN30 Trial
ASH 2024
Maintenance to end all maintenance
ENG
GMMG-HD7, GMMG-HD10/DSMM-XX (MajesTEC-5)
ASH 2024
NDMM: Strong performance by GMMG!
ENG
GMMG-HD7, HD10/DSMM-XX, (MajesTEC-5), Majestec-4/EMN30
ASH 2024
Great new developments in first-line therapy!
ENG
ASH 2024
Reshaping treatment decision-making in Newly Diagnosed…
ENG
GMMG-HD10/DSMM-XX
ASH 2024
The holy grail of MRD-negativity
Newly Diagnosed Multiple Myeloma multilanguage
GER
GMMG-HD7, GMMG-HD10/DSMM-XX (MajesTEC-5)
ASH 2024
NDMM: Starker Auftritt der GMMG!
GER
BMT CTN 0702 (STaMINA)
ASH 2024
24-Stunden-Urinsammlung im Follow-Up nicht mehr…
GER
AQUILA, CAR-PRISM
ASH 2024
Therapie des Smoldering Myeloms
GER
DREAMM-9
ASH 2024
Belantamab Mafodotin in der Erstbehandlung der nicht…
GER
GMMG-HD7, HD10/DSMM-XX, (MajesTEC-5), Majestec-4/EMN30
ASH 2024
Tolle neue Entwicklungen in der Erstlinientherapie!
Relapsed Refractory Multiple Myeloma
ENG
CARTITUDE-4, IMMagine-1
ASH 2024
Exciting development in CAR-T cell therapy for multiple…
ENG
DREAMM-7
ASH 2024
Belantamab-Vd is the SOC in 2nd line – if cilta-cel is…
ENG
ASH 2024
A new trispecific to beat them all?
ENG
MagnetisMM-20
ASH 2024
Precision medicine dissects mechanisms of…
ENG
ASH 2024
Tocilizumab prophylaxis for RRMM patients treated with…
ENG
MagnetisMM-20
ASH 2024
Combination of elranatamab + carfilzomib +…
Relapsed Refractory Multiple Myeloma multilanguage
NOR
ASH 2024
Et nytt trispesifikt antistoff, best av dem alle?
GER
CARTITUDE-4, IMMagine-1
ASH 2024
Spannende Entwicklung in der CAR-T-Zelltherapie beim…
NOR
DREAMM-7
ASH 2024
Belantamab-Vd er beste standard, hvis cilta-cel ikke er…
MGUS & Smoldering Myeloma
ENG
AQUILA
ASH 2024
Daratumumab in smoldering myeloma
ENG
AQUILA
ASH 2024
It's time to treat smoldering myeloma!
MGUS & Smoldering Myeloma multilanguage
GER
AQUILA
ASH 2024
Daratumumab beim Smoldering Myelom
NOR
AQUILA
ASH 2024
Det er på tide å behandle ulmende myelomatose
Follicular Lymphoma: Discussions
ENG
inMIND, ZUMA-5
ASH 2024
Different strategies for the treatment of R/R…
Follicular Lymphoma
ENG
Mithic-FL1
ASH 2024
Bispecific antibodies: A new option in the 1st line of…
ENG
inMIND
ASH 2024
1st results of the phase III study inMIND
ENG
ASH 2024
A new anti-CD19 / anti-CD3 monoclonal bispecific…
Follicular Lymphoma multilanguage
GER
Mithic-FL1
ASH 2024
Bispezifische Antikörper: Eine neue Option in der 1st…
ENG
inMIND
ASH 2024
Primi risultati dello studio di fase III inMIND
ENG
ASH 2024
Un nuovo anticorpo bispecifico anti-CD19/anti-CD3 per…
Indolent Lymphoma
ENG
ZUMA-5
ASH 2024
5-year follow-up of ZUMA-5
Indolent Lymphoma multilanguage
ITA
ZUMA-5
ASH 2024
Aggiornamento a 5 anni dello studio di fase II ZUMA-5
Mantle Cell Lymphoma: Discussions
ENG
TRIANGLE
ASH 2024
Progress in MCL: Treatment Patterns, Post-CAR-T…
ENG
ENRICH, ALTAMIRA, TRIANGLE, ECOG-ACRIN EA4151, OASIS II
ASH 2024
Practice Changing Data at ASH in MCL
Mantle Cell Lymphoma
ENG
ASH 2024
Synergistic chemo-free triplets ALR y ALO in first line…
ENG
ASH 2024
Sometimes, more is better: the VIPOR regimen for…
ENG
ALTAMIRA
ASH 2024
ALTAMIRA - a nordic trial for elderly patients with MCL
ENG
TRIANGLE
ASH 2024
European TRIANGLE study for younger patients with MCL
ENG
TRIANGLE
ASH 2024
Rituximab maintenance necessary after TRIANGLE?
ENG
TRIANGLE
ASH 2024
The era of ASCT Consolidation in first line might have…
ENG
TRIANGLE
ASH 2024
TRIANGLE: New standard in first-line therapy
ENG
ENRICH
ASH 2024
Primary results of the ENRICH trial
ENG
ENRICH
ASH 2024
Could older patients with MCL be treated without…
ENG
ENRICH
ASH 2024
ENRICH for elderly patients with MCL
ENG
ENRICH
ASH 2024
ASH Highlight: Is chemotherapy still necessary for…
ENG
OASIS II
ASH 2024
Interim results of the OASIS II trial
Mantle Cell Lymphoma multilanguage
ESP
ASH 2024
A veces, más sí es mejor: esquema VIPOR para LCM en…
ESP
ASH 2024
Sinergia con los tripletes sin quimio ALR y ALO en…
ESP
TRIANGLE
ASH 2024
El TAPH de consolidación en primera línea será historia…
GER
TRIANGLE
ASH 2024
Rituximab-Erhaltung nach TRIANGLE notwendig?
SWE
ALTAMIRA
ASH 2024
ALTAMIRA- en nordisk studie för äldre patienter med…
SWE
TRIANGLE
ASH 2024
TRIANGLE - en studie från det Europeiska nätverket för…
GER
TRIANGLE
ASH 2024
TRIANGLE: Der neue Standard in der Erstlinientherapie
GER
ENRICH
ASH 2024
ASH Highlight: Ist die Chemotherapie beim…
SWE
ENRICH
ASH 2024
ENRICH - vad blir standardbehandling för äldre…
ESP
ENRICH
ASH 2024
¿Podríamos tratar sin quimioterapia a los pacientes…
Chronic Small Lymphocytic Leukemia: Discussions
ENG
BRUIN CLL-321, AMPLIFY, BGB-11417-101
ASH 2024
Advances in CLL Treatment: Novel Therapies and…
Chronic/Small Lymphocytic Leukemia
ENG
BRUIN CLL-321
ASH 2024
Pirtobrutinib is superior to investigator's choice in…
ENG
BGB-11417-101
ASH 2024
Sonrotoclax + Zanubrutinib in treatment naive CLL
DLBCL
ENG
Epcore NHL-2
ASH 2024
Impressive results for fixed-duration Epcoritamab +…
ENG
Polarix
ASH 2024
5-year update from Polarix trial
ENG
ASH 2024
Initial efficacy and safety data for combination of…
